XGX Pharma
XGX Pharma is a Copenhagen-based specialty generic pharmaceutical company that licenses, develops, distributes, and sells 20+ Gx products across the Nordics, serving healthcare providers and patients through partner-driven market entry for international pharma firms.
- Company typePrivate
- Founded2014
- HeadquartersKöpenhamn, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingServices
What XGX Pharma does
XGX Pharma is a privately held Danish specialty generic (Gx) pharmaceutical company founded in 2014 and headquartered in Copenhagen. The company licenses, develops, distributes, and sells specialty generics across the Nordic region — Denmark, Sweden, Norway, Finland, and Iceland — and is actively expanding internationally. Products are sourced through three channels: in-licensing from international pharmaceutical companies, co-development with specialist partners, or outright acquisition. The portfolio is curated against the explicit criteria of addressing unmet medical needs and improving compliance for patients and healthcare professionals, and it grew from a first product launch in 2018 to more than 20 products by 2024.
The underlying operating model is asset-light and partner-mediated. XGX Pharma retains internal competencies for portfolio management and commercial execution while outsourcing formulation, laboratory work, regulatory affairs, quality assurance, and pharmacovigilance to trusted partners. The company markets itself as an end-to-end Nordic market entry provider for international pharma firms, bundling licensing, regulatory navigation, distribution, and sales into a single offering. Distribution flows via B2B partnerships with drug developers, regulatory specialists, and channel/distribution partners; products with international potential are out-licensed or divested as development progresses, creating an asset-rotation revenue lever alongside direct sales. Pricing is negotiated bilaterally under commercial and licensing agreements and is not publicly disclosed. No app, API, SDK, or AI/ML product surface is offered.
The customer base is institutional: healthcare providers and patients reached through distribution and licensing counterparties in the Nordics and select international markets. The organization is intentionally lean — a small team of 1-10 medical, regulatory, and commercial specialists led by CEO Jens-Nikolaj Schøier — and the company is GDPR-compliant under Danish data protection law. No revenue, funding total, or external investor backing is publicly disclosed. The revenue model is a mix of one-time licensing economics and ongoing product sales, with the precise split undisclosed.
XGX Pharma firmographics
Firmographics- Name
- XGX Pharma
- Legal name
- XGX Pharma
- Website
- https://xgxpharma.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- XGX Pharma is a Copenhagen-based specialty generic pharmaceutical company that licenses, develops, distributes, and sells 20+ Gx products across the Nordics, serving healthcare providers and patients through partner-driven market entry for international pharma firms.
- Ownership category
- akta.pro rank
XGX Pharma industry classification
Industry- Product category
- Specialty Generic Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industry
- Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)
Keywords
Where XGX Pharma is headquartered
LocationHeadquarters
- HQ city
- Köpenhamn
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
XGX Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- Specialty Generic Pharmaceutical Sales: Revenue generated from licensing, development, distribution and sales of specialty Gx pharmaceuticals. Products are launched and sold throughout Nordic markets and beyond. First product launched in 2018, with over 20 products sold by 2024. Products with international potential are out-licensed or divested as development progresses.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
XGX Pharma product offering
Product offeringCore offering
XGX Pharma is engaged in the licensing, development, distribution and sales of specialty generic (Gx) pharmaceuticals. The company identifies and markets products that satisfy unmet medical needs and improve compliance for patients or healthcare professionals, operating primarily across the Nordic region with plans for international expansion.
Product overview
XGX Pharma is a specialty generic (Gx) pharmaceutical company offering a portfolio of products focused on unmet medical needs with improved patient and healthcare professional compliance. Products are in-licensed, co-developed with partners, or acquired. The company operates across licensing, development, distribution, and sales, with a solid pipeline of over 20 products projected to be on the market by 2024.
Differentiator
Problem solved
Functional benefit
Products and services
- Specialty Generic Pharmaceuticals Portfolio Portfolio of specialty generic (Gx) pharmaceuticals that satisfy unmet medical needs and improve compliance for patients and healthcare professionals; products are in-licensed, developed in collaboration with partners, or acquired, and distributed primarily across the Nordic region.
- Pharmaceutical Licensing Services In-licensing of specialty Gx products from international pharmaceutical companies for Nordic commercialization, enabling partners to access the Nordic market without building a dedicated local presence.
- Pharmaceutical Development and Distribution Services Partner-led development, regulatory, quality assurance, pharmacovigilance, and distribution services delivered through a network of trusted partners for specialty Gx products marketed in the Nordic region.
Companies that use XGX Pharma
Customer profileSegments1 record
Ideal customer profiles1 record
XGX Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
XGX Pharma partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Drug Development PartnerscoreXGX Pharma partners with premium companies within drug development. Products are either in-licensed, developed in collaboration with partners, or acquired. The company works closely with partners on strategies for product formulation/development, regulatory approaches, and key processes up until launch and post marketing.
- Medical & Regulatory Affairs PartnerscorePartnerships with premium companies handling medical and regulatory affairs. XGX Pharma engages closely with partners on regulatory approaches and key processes for product development and market launch.
- Distribution PartnerscoreDistribution partnerships for getting specialty generic pharmaceuticals to market throughout the Nordic region and internationally. Products with international potential are out-licensed or divested as development progresses.
- Finance and Business Advisory PartnersminorPartnerships with finance and business advisory firms to support company growth and strategic initiatives.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
XGX Pharma competitors and assessment
Company assessmentDirect peers
- Orifarm: Danish-headquartered pharmaceutical company focused on parallel import and generic pharmaceuticals across the Nordics and Europe. Directly comparable to XGX in Nordic geographic base, generic pharma focus, and B2B distribution model.
- 2care4: Nordic pharmaceutical company specializing in parallel distribution of pharmaceuticals and consumer health products. Comparable to XGX as a Nordic B2B pharmaceutical distributor serving similar customer segments.
- Abacus Medicine: Danish-headquartered pharmaceutical company focused on parallel import and distribution of medicines across European markets. Directly comparable in Nordic origin and pharmaceutical distribution model targeting European markets.
Broad incumbents
- Sandoz: Global leader in generic pharmaceuticals and biosimilars, spun off from Novartis. Comparable as a broad incumbent in the generic pharmaceutical space in which XGX operates, though at vastly larger scale and broader geographic footprint.
- Teva Pharmaceutical: One of the world's largest generic pharmaceutical manufacturers with broad global presence. Comparable as a major incumbent in generic pharmaceuticals that competes with XGX's market segment.
- STADA Arzneimittel: European-focused generic and specialty pharmaceutical company headquartered in Germany. Comparable as a broader European generic and specialty pharma player with similar therapeutic positioning.
- Krka: Slovenian generic pharmaceutical manufacturer with strong presence in Central and Eastern Europe including the Nordics. Comparable as a European generic pharma incumbent serving similar therapeutic categories and channels.
- Perrigo: Global consumer healthcare and generic pharmaceutical company with strong European presence. Comparable as a broader generic and OTC pharma player with European market reach overlapping with XGX.
Emerging players
- Alvotech: Icelandic-headquartered biosimilar-focused pharmaceutical company with Nordic roots and international commercial ambitions. Comparable as a Nordic-origin specialty pharma with international scaling strategy and partnership-led model.
- Pharma Nord: Danish pharmaceutical and nutraceutical company with international distribution. Comparable as a Danish pharma company operating in adjacent specialty health categories with international ambitions.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
XGX Pharma social profiles
Digital presenceXGX Pharma compliance and trust
Trust signalCompliance1 record
XGX Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
XGX Pharma leadership team
Management profileNumber of profiles
Profiles1 record
XGX Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
XGX Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about XGX Pharma
What does XGX Pharma do?
XGX Pharma is engaged in the licensing, development, distribution and sales of specialty generic (Gx) pharmaceuticals. The company identifies and markets products that satisfy unmet medical needs and improve compliance for patients or healthcare professionals, operating primarily across the Nordic region with plans for international expansion.
Is XGX Pharma a public or private company?
XGX Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was XGX Pharma founded?
XGX Pharma was founded in 2014. It employs 1 to 10 people.
Where is XGX Pharma based?
XGX Pharma is headquartered in Köpenhamn, Sweden, in the Europe region.
How does XGX Pharma make money?
One revenue line is on record: specialty Generic Pharmaceutical Sales.
Who are XGX Pharma's main competitors?
Direct peers on record are Orifarm, 2care4 and Abacus Medicine. Broad incumbents are Sandoz, Teva Pharmaceutical, STADA Arzneimittel, Krka and Perrigo. Emerging players are Alvotech and Pharma Nord.
Does XGX Pharma have an API?
No public API is recorded for XGX Pharma.
What industry is XGX Pharma in?
XGX Pharma's product category is Specialty Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of CRAOAHAA, Prescription Pharmaceutical (Rx) Wholesale Distribution. Its NAICS code is 32541 and its SIC code is 2834.